VIDEO: Faricimab may demonstrate better drying of pigment epithelial detachments
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Jennifer I. Lim, MD, discusses the effect of faricimab on pigment epithelial detachments.
Patients received monthly doses of either faricimab or aflibercept for the treatment of neovascular age-related macular degeneration. After 12 weeks, Lim and colleagues evaluated the drying effect of each drug.
Lim said there was not a difference between the two groups with fibrovascular pigment epithelial detachments (PEDs), but in serous PEDs, 3.9% of eyes treated with faricimab still had a serous PED component compared with 12.3% of eyes treated with aflibercept.
“It tells us that, indeed, the faricimab treatment could result in better drying of the PED compared to aflibercept, much like it does for all other fluid compartments,” Lim said.
Collapse
Lim JI, et al. How effective is anti-Ang2 and anti-VEGF (faricimab) for neovascular AMD with pigment epithelial detachments? Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts